Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
about
Screening for prostate cancerRadical prostatectomy versus watchful waiting for prostate cancerScreening for prostate cancerIntraoperative Optical Biopsy during Robotic Assisted Radical Prostatectomy Using Confocal Endomicroscopy.Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trialComparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis.Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.Radical prostatectomy or watchful waiting in early prostate cancer.Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer.Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaProstate-specific antigen screening can be beneficial to younger and at-risk men.Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.Quality of life in men undergoing active surveillance for localized prostate cancer.Controversies on individualized prostate cancer care: gaps in current practice.Intrusive thoughts and quality of life among men with prostate cancer before and three months after surgery.Clinicopathological study of 9 cases of prostate cancer involving the rectal wall.Screening for prostate cancer: an updated Cochrane systematic review.When is active surveillance the appropriate treatment for prostate cancer?Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study.Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant)Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection.Analysis of urological procedures in men who died from prostate cancer using a population-based approach.Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer.Health-related quality of life outcomes in Scandinavian patients after radical prostatectomy or watchful waiting: a critical appraisal.National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands.Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upProstate cancer survivorship care in the Veterans Health Administration
P2860
Q24201690-43F7582C-EA6E-44C3-AB18-06332D792FFEQ24236564-014AEA3D-12FE-4224-BCD6-D1B3828364EDQ24245476-01FAD62C-7CE7-47CD-84C7-D4656F3C34CEQ30762097-4E5B35A5-04B5-4B16-8D1B-EDAAF40711D2Q30845863-FE63C18B-CC1F-45D1-B565-F71BC0A1322EQ33626084-EEF8458F-934A-4309-98B0-3EF062133411Q33855285-3CA988EB-91F0-41F0-B1B1-2A4166140C91Q33985455-0B060706-3885-4A9C-8646-19A19668AA1EQ34383168-FC20EAAF-804A-407B-A130-6CC52FA4F9FDQ35541638-1F2230CE-A644-4E3D-A158-AB26244E82C3Q36510711-7D73D22D-EF95-48B1-BFA5-AE7A7A22F774Q36520496-454EC41D-9E5B-44C2-B1F9-652AE34F2F0EQ36520543-F42CFF78-E05F-4358-9C5D-B3D53121B14CQ37149085-0A2FC8F7-6203-4C80-B491-44BF75E849F2Q37357793-14585706-B88D-4AC7-87FD-B2F4EFA24860Q37589249-D5D837FB-F18C-4AC9-9EDA-0D758055FABEQ37851577-7DECAF47-393A-451E-852E-2A6DF53FB999Q37878475-6B0D7F0E-C50A-4597-A218-0A70D79FD1B6Q38539324-C76CBCD4-AFD3-4D7E-8AAD-D5888D772385Q38626224-4BE06D7E-F7D8-4FD3-B23C-D970617001DEQ38804659-6DDCE806-BF52-4528-8E20-A5C6C5FE4BA8Q39607551-CF75E78B-5487-4C19-AF58-BBB852046FB7Q40100788-ECB82192-5F22-40A0-A694-DB67A85938BEQ41786389-72B71534-139C-4E01-B218-D138EDCCF9EFQ41816104-09CE484D-4C71-4678-B510-BED334D569E2Q42140812-885E0F6B-5A13-46BF-9CD3-38CADE111B1AQ42642983-65EE767F-CCA0-43E7-A8A1-850BCED7FC58Q45307605-81011E76-7C26-4C32-B08E-E48FC4B3BD54Q47312777-4D688615-D099-4D6D-8475-AF05741C9CDBQ48070488-5383C6C0-DD80-42B0-8D76-60099A724E29Q57278890-0AE63010-8171-4DCA-90DA-0318BA999719Q58134906-A2708B08-B239-4660-A519-A5327291A5E3
P2860
Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@en
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@nl
type
label
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@en
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@nl
prefLabel
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@en
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@nl
P2093
P1433
P1476
Time, symptom burden, androgen ...... ber 4 (SPCG-4) clinical trial.
@en
P2093
Anna Bill-Axelson
Erik Onelöv
Eva Johansson
Jan-Erik Johansson
Scandinavian Prostate Cancer Group Study No 4
P304
P356
10.1016/J.EURURO.2008.08.054
P407
P577
2008-09-02T00:00:00Z